Target intelligence / Profile preview

Ubiquitin carboxyl-terminal hydrolase 17-like protein 1 (USP17L1)

Target
USP17L1
Molecular classification
Enzyme, Deubiquitinating enzyme, Cysteine-type peptidase, Ubiquitin-specific protease family
01

Overview

Ubiquitin carboxyl-terminal hydrolase 17-like protein 1 (USP17L1) is a cysteine-type deubiquitinating enzyme that removes ubiquitin from conjugated proteins to regulate cellular functions such as protein stability, cell proliferation, the cell cycle, apoptosis, cell migration, and response to viral infection[2][3]. It belongs to the ubiquitin-specific protease family, whose members influence cellular homeostasis by recycling ubiquitin and modulating the degradation and function of numerous protein substrates. Evidence for direct disease association, biomarkers, or drug interactions specific to USP17L1 is currently lacking, but the family is broadly studied in cancer biology and infection. USP17L1 is predicted to localize to the cytosol, nucleus, and endoplasmic reticulum, reflecting roles in diverse intracellular processes[2].

Other names
USP17L1Ubiquitin specific peptidase 17 like family member 1Deubiquitinating enzyme 17-like protein 1Ubiquitin thioesterase 17-like protein 1Ubiquitin-specific-processing protease 17-like protein 1USP17LUSP17L1Pputative ubiquitin carboxyl-terminal hydrolase 17-like protein 1
02

Mechanism of action

Inhibition of deubiquitinating activity (theoretical; no known drugs) Modulation of cell cycle regulation, apoptosis, and protein stability via effects on ubiquitin removal

03

Biological functions

Deubiquitination—removes conjugated ubiquitin from specific proteinsRegulation of protein stabilityRegulation of apoptotic processCell proliferationProgression through cell cycleCell migrationCellular response to viral infection
04

Disease associations

Cancer (based on the general roles of deubiquitinases in cell proliferation, apoptosis, and stability)Infection (cellular response to viral infection)Other (any pathology where protein ubiquitination is perturbed)
05

Safety considerations

Off-target effects: Broad inhibition of deubiquitinases could affect fundamental cellular processes (proliferation, apoptosis)Potential for toxicity if protein stability or cell cycle regulation is disruptedSpecific safety profile for USP17L1-targeted drugs unknown (no approved drugs)
06

Interacting drugs

None known or reported in current sources
07

Biomarkers

None specifically identified for USP17L1

Beyond the preview

Go deeper on Ubiquitin carboxyl-terminal hydrolase 17-like protein 1 (USP17L1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ubiquitin carboxyl-terminal hydrolase 17-like protein 1 (USP17L1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call